EE04223B1 - Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid - Google Patents

Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid

Info

Publication number: EE04223B1
Authority: EE; Estonia
Prior art keywords: interferon; liquid; amino acids; liquid formulation; formulation containing
Prior art date: 1996-12-24

Application number

EEP199900313A

Other languages

English (en)

Estonian (et)

Other versions

EE9900313A (et

Inventor

D. Dibiasi Mary

Staples Mark

Chung Wen-Li

Scharin Eric

Original Assignee

Biogen, Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-24

Filing date

1997-12-23

Publication date

2004-02-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-23 Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated

2000-04-17 Publication of EE9900313A publication Critical patent/EE9900313A/xx

2004-02-16 Publication of EE04223B1 publication Critical patent/EE04223B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EEP199900313A 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid EE04223B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3435396P	1996-12-24	1996-12-24
PCT/US1997/023817 WO1998028007A1 (en)	1996-12-24	1997-12-23	Stable liquid interferon formulations

Publications (2)

Publication Number	Publication Date
EE9900313A EE9900313A (et)	2000-04-17
EE04223B1 true EE04223B1 (et)	2004-02-16

Family

ID=21875893

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EEP200300127A EE04266B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon
EEP199900313A EE04223B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EEP200300127A EE04266B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon

Country Status (27)

Country	Link
EP (1)	EP0948358B2 (pt)
JP (5)	JP4878664B2 (pt)
KR (2)	KR101042660B1 (pt)
CN (2)	CN1733296B (pt)
AT (1)	ATE270899T1 (pt)
AU (1)	AU738362B2 (pt)
BG (2)	BG65171B1 (pt)
BR (1)	BR9714434A (pt)
CA (1)	CA2275890C (pt)
CZ (1)	CZ300636B6 (pt)
DE (1)	DE69729880T3 (pt)
DK (1)	DK0948358T4 (pt)
EA (1)	EA002754B1 (pt)
EE (2)	EE04266B1 (pt)
ES (1)	ES2224290T5 (pt)
HU (1)	HU224222B1 (pt)
IL (1)	IL130524A (pt)
IS (1)	IS2070B (pt)
MX (1)	MX337876B (pt)
NO (1)	NO327844B1 (pt)
NZ (2)	NZ336548A (pt)
PL (1)	PL193447B1 (pt)
PT (1)	PT948358E (pt)
SI (1)	SI0948358T2 (pt)
SK (1)	SK284989B6 (pt)
TR (1)	TR199901968T2 (pt)
WO (1)	WO1998028007A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
TR199901968T2 (xx) *	1996-12-24	1999-12-21	Biogen, Inc.	Sabit s�v� interferon form�lleri.
ES2181281T5 (es) *	1997-09-23	2008-04-16	Rentschler Biotechnologie Gmbh	Formulaciones liquidas de interferon beta.
ES2408784T3 (es) *	1999-05-31	2013-06-21	Mitsubishi Chemical Corporation	Preparaciones liofilizadas de HGF
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
AR034749A1 (es) *	2001-07-09	2004-03-17	Schering Ag	Formulaciones de interferon beta humano
WO2003055512A1 (en)	2001-12-21	2003-07-10	Novo Nordisk Health Care Ag	Liquid composition of factor vii polypeptides
US20060083733A1 (en) *	2002-01-18	2006-04-20	Fumihide Nishio	High-concentration preparation of soluble thrombomodulin
PL207018B1 (pl)	2002-06-21	2010-10-29	Novo Nordisk Helth Care Ag	Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
TWI272948B (en) *	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
AR044302A1 (es) *	2003-05-13	2005-09-07	Ares Trading Sa	Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
ATE454900T1 (de)	2003-05-23	2010-01-15	Novo Nordisk Healthcare Ag	Stabilisierung von proteinen in lösung
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
KR20120104619A (ko)	2003-08-14	2012-09-21	노보 노르디스크 헬스 케어 악티엔게젤샤프트	인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
CA2546280A1 (en) *	2003-11-13	2005-06-09	Alza Corporation	Composition and apparatus for transdermal delivery
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
CN1917861B (zh)	2003-12-19	2012-03-21	诺和诺德医疗保健公司	因子vii多肽的稳定化固体组合物
JP2008500995A (ja) *	2004-06-01	2008-01-17	アレストレーディングソシエテアノニム	タンパク質安定化法
US20080193997A1 (en) *	2004-08-24	2008-08-14	Kenji Kangawa	Liquid Preparation of Physiologically Active Peptide
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PT1809662E (pt)	2004-11-10	2009-02-26	Novartis Vaccines & Diagnostic	Interferão beta desamidado
LT1845925T (lt) *	2005-01-12	2016-09-26	Biogen Ma Inc.	Interferono-beta pateikimo būdas
AU2006206272A1 (en) *	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
DK1899462T3 (da)	2005-07-02	2011-06-06	Arecor Ltd	Stabile vandige systemer omfattende proteiner
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
NZ573360A (en)	2006-05-04	2012-08-31	Boehringer Ingelheim Int	Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PT2868315T (pt) *	2007-12-04	2017-09-04	Remedy Pharmaceuticals Inc	Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
AU2008340058A1 (en)	2007-12-20	2009-07-02	Merck Serono S.A.	PEG-interferon-beta formulations
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
WO2009133408A2 (en)	2008-05-01	2009-11-05	Arecor Limited	Protein formulation
EP2328607A1 (en)	2008-07-16	2011-06-08	Arecor Limited	Stable formulation of a therapeutic protein
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009290911A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de)	2008-10-14	2010-04-15	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es)	2008-12-23	2011-07-13	Boehringer Ingelheim Int	Formas salinas de compuesto organico.
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de)	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
AU2010323068B2 (en)	2009-11-27	2015-09-03	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
TR201903403T4 (tr)	2010-02-04	2019-04-22	Csl Behring Ag	İmmünoglobulin preparatı.
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) *	2010-03-15	2011-09-15	Kurt Koch	Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011161161A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Diabetes therapy
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
CN103260616B (zh) *	2010-12-09	2015-09-09	丸石制药株式会社	对乙酰氨基酚的稳定化剂
EP2686002B1 (en)	2011-03-15	2018-01-24	Biogen Inc.	Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
WO2013010964A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013159057A1 (en) *	2012-04-19	2013-10-24	C. R. Bard, Inc.	Infusates with enhanced ph stability under ethylene oxide sterilization
EP2849755A1 (en)	2012-05-14	2015-03-25	Boehringer Ingelheim International GmbH	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en)	2012-05-14	2022-09-14	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) *	2012-05-28	2013-11-29	Nicoletta Maxia	Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) *	2013-03-07	2014-11-05	安徽安科生物工程（集团）股份有限公司	一种重组人干扰素α2b制剂
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) *	2014-06-17	2014-11-06	株式会社スリー・ディー・マトリックス	タンパク質の凝集抑制剤
DK3763384T3 (da)	2014-12-03	2024-09-23	Csl Behring Ag	Farmaceuitisk produkt med øget stabilitet, omfattende immunoglobuliner
JP2019517542A (ja)	2016-06-10	2019-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	リナグリプチンおよびメトホルミンの組合せ
KR101943160B1 (ko) *	2016-10-06	2019-01-30	에이비온 주식회사	인터페론 베타 변이체의 안정화 제제
PL3672631T3 (pl)	2017-08-22	2023-06-26	Biogen Ma Inc.	Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi
KR102731889B1 (ko) *	2019-07-18	2024-11-19	에이비온 주식회사	2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) *	2019-11-20	2023-04-07	迈克生物股份有限公司	蛋白c活性测定试剂盒
WO2021221485A1 (ko) *	2020-04-29	2021-11-04	에이비온 주식회사	이중 돌연변이를 가지는 인간 인터페론-베타 변이체 및 인간 인터페론-베타 변이체의 안정성을 향상시키는 방법
WO2022207655A1 (en) *	2021-03-30	2022-10-06	Schott Schweiz Ag	System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) *	2021-11-29	2024-05-28	苏州人本药业有限公司	一种含有神经毒素的液体制剂及其制备方法
CA3242509A1 (en) *	2021-12-27	2023-07-06	Joseph V. Pergolizzi	Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57175125A (en) *	1981-04-20	1982-10-28	Wakunaga Yakuhin Kk	Preparation of beta-interferon
EP0082481B2 (en) *	1981-12-23	1990-09-12	Schering Corporation	Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
JPS63196268A (ja) *	1987-02-10	1988-08-15	Kanegafuchi Chem Ind Co Ltd	無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
US4895716A (en) *	1987-06-09	1990-01-23	Biogen, Inc.	Stabilized formulations of gamma interferons
JPH02124832A (ja) *	1988-07-08	1990-05-14	Toray Ind Inc	インターヘェロンβ組成物
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) *	1993-05-12	2001-01-28	Genentech Inc	Stable liquid compositions of gamma interferon
TW249202B (pt) *	1993-08-13	1995-06-11	Ciba Gerigy Corp
US5545723A (en) *	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
HUT74900A (en) *	1994-04-08	1997-02-28	Brigham & Womens Hospital	Treatment of autoimmune disease using oral tolerization and/or type i interferon
IT1272252B (it) *	1994-05-16	1997-06-16	Applied Research Systems	Formulazioni liquide di interferone beta
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
TR199901968T2 (xx) *	1996-12-24	1999-12-21	Biogen, Inc.	Sabit s�v� interferon form�lleri.

1997
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 EE EEP200300127A patent/EE04266B1/xx unknown
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 EE EEP199900313A patent/EE04223B1/xx unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Ceased
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
1999
- 1999-06-21 IS IS5087A patent/IS2070B/xx unknown
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN1733296A (zh)	2006-02-15
HK1025040A1 (en)	2000-11-03
SK284989B6 (sk)	2006-04-06
BG109523A (en)	2007-05-31
AU738362B2 (en)	2001-09-13
KR20000069664A (ko)	2000-11-25
EE9900313A (et)	2000-04-17
JP2012006979A (ja)	2012-01-12
SI0948358T1 (en)	2005-04-30
HUP0000829A2 (en)	2000-07-28
DK0948358T3 (da)	2004-11-08
EE04266B1 (et)	2004-04-15
EA002754B1 (ru)	2002-08-29
ES2224290T3 (es)	2005-03-01
CZ300636B6 (cs)	2009-07-08
JP4878664B2 (ja)	2012-02-15
CA2275890C (en)	2011-11-01
CA2275890A1 (en)	1998-07-02
ATE270899T1 (de)	2004-07-15
TR199901968T2 (xx)	1999-12-21
NO993121L (no)	1999-08-24
PL193447B1 (pl)	2007-02-28
BR9714434A (pt)	2000-05-02
ES2224290T5 (es)	2012-03-12
SI0948358T2 (sl)	2012-03-30
PT948358E (pt)	2004-10-29
IL130524A0 (en)	2000-06-01
EP0948358B1 (en)	2004-07-14
HK1092048A1 (zh)	2007-02-02
SK85899A3 (en)	2000-01-18
NZ512792A (en)	2002-11-26
KR20070052363A (ko)	2007-05-21
CZ228299A3 (cs)	1999-12-15
JP2014098029A (ja)	2014-05-29
BG103594A (en)	2000-04-28
DK0948358T4 (da)	2012-03-19
AU5619198A (en)	1998-07-17
DE69729880T3 (de)	2012-05-10
MX337876B (es)	2016-03-22
EP0948358A1 (en)	1999-10-13
EP0948358B2 (en)	2011-11-23
HUP0000829A3 (en)	2002-01-28
IS2070B (is)	2005-12-15
NO327844B1 (no)	2009-10-05
JP5851695B2 (ja)	2016-02-03
JP2007204501A (ja)	2007-08-16
HU224222B1 (hu)	2005-06-28
NZ336548A (en)	2001-09-28
NO993121D0 (no)	1999-06-23
EE200300127A (et)	2003-06-16
BG65418B1 (bg)	2008-07-31
IS5087A (is)	1999-06-21
CN1222315C (zh)	2005-10-12
EA199900597A1 (ru)	2000-02-28
WO1998028007A1 (en)	1998-07-02
CN1733296B (zh)	2010-05-26
CN1245434A (zh)	2000-02-23
IL130524A (en)	2005-08-31
JP2011068694A (ja)	2011-04-07
KR101042660B1 (ko)	2011-06-20
BG65171B1 (bg)	2007-05-31
DE69729880T2 (de)	2005-07-07
DE69729880D1 (de)	2004-08-19
PL334365A1 (en)	2000-02-28
JP2001519770A (ja)	2001-10-23

Publication	Publication Date	Title
EE04223B1 (et)	2004-02-16	Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
CA2113995A1 (en)	1993-03-18	Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
IL95118A0 (en)	1991-06-10	Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
AU586892B2 (en)	1989-07-27	Pharmaceutical and dietary composition
DE3166150D1 (en)	1984-10-25	N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
TW364850B (en)	1999-07-21	Nematocidal compositions
AU4009789A (en)	1990-03-08	Recombinant natural killer cell activator
LTIP610A (en)	1994-12-27	Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
AU678421B2 (en)	1997-05-29	Highly concentrated TCF pharmaceutical preparations
AU3494093A (en)	1994-08-15	S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en)	1983-06-08	Compositions containing secretin and method for preventing the adsorption of secretin
CA2153071A1 (en)	1994-07-21	Derivatized calcitonins
KR860003012A (ko)	1986-05-19	(-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물

Legal Events

Date	Code	Title	Description
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-10-17	HC1A	Change of owner name
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231